Literature DB >> 22308514

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.

John M Salsman1, Steven M Grunberg, Jennifer L Beaumont, Miriam Rogers, Diane Paul, Marla L Clayman, David Cella.   

Abstract

Despite recent progress, chemotherapy-induced nausea and vomiting (CINV), especially delayed CINV, continues to be a problem. Delayed CINV is underestimated and perceived differently by providers and patients. Communication between providers and patients about this side effect may help improve outcomes. This study identifies patients' and providers' perceptions of management and barriers to quality CINV care. Provider and patient versions of a Nausea and Vomiting Management Barriers Questionnaire were developed to address potential barriers. Providers and patients were given opportunities to add detail in open-ended questions. Providers were recruited through the NCCN and the Oncology Nursing Society mailing lists. Patients who received at least 2 cycles of chemotherapy and experienced CINV were recruited through a consortium of advocacy groups. Both providers (n = 141) and patients (n = 299) completed the survey. Providers (41%) and patients (42%) agreed medication side effects were a concern, but more patients (63%) than providers (36%) tried to limit the number of medications taken (P < .0001). Many providers (67%) spontaneously reported barriers to managing CINV, with financial and patient-related factors among the most common. Few patients (10%) reported cost as a barrier, but 37% endorsed the desire "to be strong by not complaining." Barriers to communication and quality care of CINV differ between caregivers and patients. Addressing misconceptions and establishing mutually consistent goals will lead to more effective overall care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308514     DOI: 10.6004/jnccn.2012.0018

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  28 in total

1.  Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Authors:  Mallika P Patel; Sarah Woodring; Dina M Randazzo; Henry S Friedman; Annick Desjardins; Patrick Healy; James E Herndon; Frances McSherry; Eric S Lipp; Elizabeth Miller; Katherine B Peters; Mary Lou Affronti
Journal:  Support Care Cancer       Date:  2019-08-22       Impact factor: 3.603

2.  Self-Care Support for Patients with Gastrointestinal Cancer: iCancerHealth.

Authors:  Donna L Berry; Traci M Blonquist; Manan M Nayak; Nina Grenon; Thaer G Momani; Nadine J McCleary
Journal:  Appl Clin Inform       Date:  2018-11-21       Impact factor: 2.342

3.  Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer.

Authors:  Eriko Aotani; Tetsutaro Hamano; Akihiko Gemma; Masahiro Takeuchi; Toru Takebayashi; Kunihiko Kobayashi
Journal:  Int J Clin Oncol       Date:  2016-02-15       Impact factor: 3.402

4.  Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.

Authors:  Matti Aapro; Florian Scotté; Yolanda Escobar; Luigi Celio; Richard Berman; Alessandra Franceschetti; Danielle Bell; Karin Jordan
Journal:  Oncologist       Date:  2021-03-17

5.  Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.

Authors:  Selma Calcagnile; Corinna Lanzarotti; Giorgia Rossi; Anders Henriksson; Klaus Peter Kammerer; Wolfgang Timmer
Journal:  Support Care Cancer       Date:  2013-06-11       Impact factor: 3.603

6.  Impact of discriminant factors on the comfort-care of nurses caring for trans-arterial chemoembolisation patients.

Authors:  Myoung Soo Kim; Ju-Yeon Uhm
Journal:  Support Care Cancer       Date:  2022-06-16       Impact factor: 3.359

7.  Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China.

Authors:  Xianglong Zong; Jie Zhang; Xin Ji; Jie Gao; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

8.  Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.

Authors:  Emily S Van Laar; Jayashri Mehta Desai; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2015-01       Impact factor: 3.603

9.  Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.

Authors:  Luigi Celio; Francesca Ricchini; Filippo De Braud
Journal:  Patient Prefer Adherence       Date:  2013-05-07       Impact factor: 2.711

10.  Helping patients discuss CINV management: development of a Patient Charter.

Authors:  Annie Young; Pascale Dielenseger; Paz Fernandez Ortega; Dolores Fernandez Perez; Philippa Jones; Elaine Lennan; Eileen O'Donovan; Sue Sharp; Alison Whiteford; Lilian Wiles
Journal:  Ecancermedicalscience       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.